Objective To investigate the adverse reactions and survival rate of low dose of Oxaliplatin combined with transcatheter arterial chemoembolization in treatment of elderly patients with primary hepatic carcinoma.Methods A total of 84 patients with primary liver cancer were enrolled and randomly divided into low dose group and high dose group.Patients received 40 mg/m2 and 80 mg/m2 of Oxaliplatin respectively,and adverse reactions and survival rate were compared between the two groups.Results Incidence of nausea and vomiting was obviously lower and the number of patients with pain scale above 6 was significantly smaller in low dose group than in high dose group,with statistically significant differences (11.9％ vs.21.4％ and 28.6％ vs.78.6％,x2 =9.910,20.056,both P ＜ 0.05).White blood cell count was significantly higher and alanine aminotransferase (ALT) was significantly lower in low dose group than in high dose group after treatment (t =13.447,6.774,both P＜0.05).1 year and 3 year survival rate was 69.05％ and 30.95％ in low dose group and 61.9％ and 21.43％ in high dose group,respectively,with no statistically significant difference (x2 =0.474 and 0.985,P=0.491 and 0.321).Conclusions Low dose of Oxaliplatin combined with transcatheter arterial chemoembolization in the treatment of elderly patients with primary hepatocellular carcinoma is worth to be promoted in clinical application because it does not affect the patient survival rate and the toxic effects of the chemotherapy are very little.%目的 研究低剂量奥沙利铂联合肝动脉化疗栓塞术在老年原发性肝癌治疗中的不良反应和生存期. 方法 选取84例原发性肝癌患者,按照随机数表法将患者分成低剂量组和高剂量组,分别采用奥沙利铂剂量为40 mg/m2和80 mg/m2,对比两组患者的不良反应和存活率情况.结果 低剂量组恶心、呕吐的发生率明显低于高剂量组(11.9％和21.4％,x2=9.910,P＜0.05).低剂量组患者疼痛评分在6以上的患者,要明显少于高剂量组(28.6％和78.6％,x2=20.056,P＜0.05),治疗后的白细胞计数明显高于高剂量组,丙氨酸转氨酶低于高剂量组(t=13.447和6.774,均P＜0.05);低剂量组患者的1年期、3年期存活率分别为69.05％、30.95％,略高于高剂量组的61.9％、21.43％,差异无统计学意义(x2=0.474和0.985,均P=0.491和0.321). 结论 低剂量奥沙利铂联合肝动脉化疗栓塞术治疗老年原发性肝癌,化疗的毒副反应很小,且不会影响患者的存活率,值得在临床上推广应用.
展开▼
